Health Care [ 8/12 ] | Pharmaceuticals [ 50/74 ]
NASDAQ | Common Stock
Supernus Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes products for the treatment of central nervous system (CNS) diseases in the United States.
The company offers Qelbree, a non-stimulant indicated for the treatment of attention-deficit hyperactivity disorder (ADHD); GOCOVRI for the treatment of dyskinesia and levodopa/carbidopa in patients with Parkinson's Disease (PD); Oxtellar XR, an extended-release oxcarbazepine product indicated for the monotherapy treatment of partial onset epilepsy seizures; and APOKYN for the acute and intermittent treatment of hypomobility or off episodes in patients with advanced PD.
It also provides Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; XADAGO for the treatment of levodopa/carbidopa in patients with PD experiencing off episodes; and MYOBLOC, a Type B toxin product indicated for the treatment of cervical dystonia and chronic sialorrhea.
In addition, the company develops ONAPGO, which received FDA approval, for the treatment of motor fluctuations in adults with advanced PD; SPN-817, a first-in-class selective acetylcholinesterase inhibitor, which is in Phase 2 clinical trial, for the treatment of epilepsy, partial seizures, Dravet syndrome, and Lennox-Gaustaut syndrome; SPN-820, a small molecule in Phase 2 clinical trial for treating resistant depression; SPN-443, a stimulant in Phase 1 trial for the treatment of ADHD/CNS; and SPN-446, a preclinical product for CNS.
It markets and sells its products through pharmaceutical wholesalers, specialty pharmacies, and distributors.
It has a development agreement with Navitor Inc. for the conduct of Phase 2 clinical program of SPN-820.
Supernus Pharmaceuticals, Inc. was incorporated in 2005 and is based in Rockville, Maryland.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Feb 25, 25 | 0.55 Decreased by -38.39% | 0.52 Increased by +5.44% |
| Nov 4, 24 | 0.69 Increased by +187.50% | 0.44 Increased by +56.82% |
| Aug 6, 24 | 0.36 Increased by +1.90 K% | 0.31 Increased by +16.13% |
| May 8, 24 | 0.26 Decreased by -10.34% | 0.38 Decreased by -31.58% |
| Feb 27, 24 | 0.89 Increased by +106.98% | 0.55 Increased by +61.82% |
| Nov 8, 23 | 0.24 Increased by +700.00% | 0.08 Increased by +200.00% |
| Aug 8, 23 | -0.02 Decreased by -114.29% | -0.23 Increased by +91.30% |
| May 9, 23 | 0.29 Decreased by -32.56% | 0.17 Increased by +70.59% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Dec 31, 24 | 174.16 M Increased by +5.99% | 15.33 M Increased by +1.20 K% | Increased by +8.80% Increased by +1.13 K% |
| Sep 30, 24 | 175.69 M Increased by +14.17% | 38.50 M Increased by +340.97% | Increased by +21.91% Increased by +311.06% |
| Jun 30, 24 | 168.32 M Increased by +24.17% | 19.92 M Increased by +2.50 K% | Increased by +11.83% Increased by +2.03 K% |
| Mar 31, 24 | 143.64 M Decreased by -6.58% | 124.00 K Decreased by -99.27% | Increased by +0.09% Decreased by -99.22% |
| Dec 31, 23 | 164.31 M Decreased by -1.80% | 1.18 M Decreased by -95.39% | Increased by +0.72% Decreased by -95.30% |
| Sep 30, 23 | 153.88 M Decreased by -13.24% | -15.98 M Decreased by -1.01 K% | Decreased by -10.38% Decreased by -1.15 K% |
| Jun 30, 23 | 135.56 M Decreased by -20.28% | -831.00 K Decreased by -110.57% | Decreased by -0.61% Decreased by -113.25% |
| Mar 31, 23 | 153.76 M Decreased by -3.32% | 16.95 M Increased by +594.02% | Increased by +11.02% Increased by +617.88% |